Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CF Patients' COVID antibodies tracked in Two-Year study

NCT ID NCT05054582

Knowledge-focused Sponsor: Medical University Innsbruck Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with cystic fibrosis (CF) have COVID-19 antibodies from infection or vaccination. Researchers followed 152 adults and children with CF for two years, taking blood samples every six months. They aimed to understand how many had antibodies, how long they lasted, and how COVID-19 affected their CF symptoms. The study did not test any new treatment but gathered important information to guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

152 people

The number who actually took part.

Started

Sep 2021

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity Exclusion Criteria: * Refusal to give informed consent * Contraindication to venepuncture

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis Digestive System Diseases hereditary disease Infant, Newborn, Diseases lung disorder pancreas disorder Pathologic Processes respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Cystic fibrosis

Contacts and locations

Locations

  • CF Centre Innsbruck, Medical University of Innsbruck, Univ. Clinic for Paediatics III

    Innsbruck, Tyrol, 6020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.